*October 2018* by Shalmali Pal Medpage Today and ASCO
Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early 2018 when it was named the “Advance of the Year” in the ASCO Annual Report. Versions of CAR-T cell therapy have shown promise for extending survival in previously incurable forms of leukemia, lymphoma, and myeloma.
“T cells are the smartest and most potent part of our immune system,” noted Crystal Mackall, MD, a pediatric oncologist a Stanford Children’s Health in California. “Immunotherapy with CAR-T cells is a new way of treating leukemia that we think is more precise, more specific, and just as potent – maybe even more potent – than chemotherapy.” Read more.
